Pharmacological upregulation of pgc1α in oligodendrocytes: Implications for huntington’s disease

Journal of Huntington's Disease

Volumn 2, Issue 1, 2013, Pages 101-105

  Xiang, Zhongmin ^a   Krainc, Dimitri ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Differentiation; Huntington s disease; Oligodendrocyte; PGC1 ; Resveratrol; SIRT1

Indexed keywords

FUSED HETEROCYCLIC RINGS; PPARGC1A PROTEIN, MOUSE; RESVERATROL; SEROTONIN TRANSPORTER; SIRTUIN 1; SLC6A4 PROTEIN, MOUSE; SRT1720; STILBENE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL DIFFERENTIATION; DIFFERENTIATION; DRUG EFFECT; GENETICS; HUNTINGTON CHOREA; METABOLISM; MOUSE; MUTATION; OLIGODENDROGLIA; PGC1Α; SIRT1; UPREGULATION;

DIFFERENTIATION; HUNTINGTON'S DISEASE; OLIGODENDROCYTE; PGC1Α; RESVERATROL; SIRT1;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUNTINGTON DISEASE; MICE; MUTATION; OLIGODENDROGLIA; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIRTUIN 1; STILBENES; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84906922582     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-130046     Document Type: Article

References (22)

1. Finck BN, Kelly DP. PGC-1 coactivators: Inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116(3): 615-22.
2. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006;127(1): 59-69.
3. Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, BeyerRP, Easley CN, SmithAC, Krainc D, Luquet S, Sweet IR, SchwartzMW, La Spada AR. Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1alpha in Huntington’s disease neurodegeneration. Cell Metab. 2006;4(5): 349-62.
4. Tsunemi T, Ashe TD, Morrison BE, Soriano KR, Au J, Roque RA, Lazarowski ER, Damian VA, Masliah E, La Spada AR. PGC-1α rescues Huntington’s disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med. 2012;4(142): 142.
5. Zuccato C, Valenza M, Cattaneo E. Molecular Mechanisms and Potential Therapeutical Targets in Huntington ' s Disease. Physiol Rev. 2010;905-81.
6. Xiang Z, Valenza M, Cui L, Leoni V, Jeong HK, Brilli E, Zhang J, Peng Q, DuanW, Reeves SA, Cattaneo E, Krainc D. Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington’s disease. J Neurosci. 2011;31(26): 9544-53.
7. Shin-ichiro Imai and Leonard Guarente. 10 Years of NADDependent SIR2 Family Deacetylases- Implications for Metabolic Diseases. Trends Pharmacol Sci. 2010;31(5): 212-20.
8. Lin T, Xiang Z, Cui L, Stallcup W, Reeves S. New mouse oligodendrocyte precursor (mOP) cells for studies on oligodendrocyte maturation and function. J Neurosci Meth. 2006;157(2): 187-94.
9. Amat R, Planavila A, Chen SL, Iglesias R, Giralt M, Villarroya F. SIRT1 controls the transcription of the peroxisome proliferator-activated receptor-gamma Co-activator-1alpha (PGC-1alpha) gene in skeletal muscle through the PGC-1alpha autoregulatory loop and interaction with MyoD. J Biol Chem. 2009;284(33): 21872-80.
10. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;434: 113-8.
11. Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, Yates JR, 3rd, Bordone L, Guarente L, Krainc D. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nature Med. 2012;18(1): 159-65.
12. Philp A, Chen A, Lan D, Meyer GA, Murphy AN, Knapp AE, Olfert IM, McCurdy CE, Marcotte GR, Hogan MC, Baar K, Schenk S. Sirtuin 1 (SIRT1) deacetylase activity is not required for mitochondrial biogenesis or peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) deacetylation following endurance exercise. J Biol Chem. 2011;286(35): 30561-70.
13. Milne JC, Lambert PD, Schenk S, CarneyDP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2009;450(7170): 712-6.
14. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15(5): 675-90.
15. Eaton JS, Lin ZP, Sartorelli AC, Bonawitz ND, Shadel GS. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest. 2007;117(9).
16. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010;285(11): 8340-51.
17. Beher D, Wu J, Cumine S, Kim KW, Lu S-C, Atangan L, Wang M. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des. 2009;74(6): 619-24.
18. Jäger S, Handschin C, St-Pierre J, Spiegelman BM. AMPactivated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA. 2007;104(29): 12017-22.
19. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA. 2007; 104(17): 7217-22.
20. Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC, Lambert PD, Mataki C, Elliott PJ, Auwerx J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008;8(5): 347-58.
21. Cantó C, Auwerx J. AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci. 2010;67(20): 3407-23.
22. Ho DJ, CalingasanNY, Wille E, Dumont M, BealMF. Resveratrol protects against peripheral deficits in a mouse model of Huntington’s disease. Exp Neurol. 2010;225(1): 74-84.